Patient considerations in metastatic colorectal cancer – role of panitumumab

• Main Author: Rogers JE
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-04-01
• Series: OncoTargets and Therapy
• Subjects: panitumumab; antineoplastic agent; antibodies; monoclonal; colorectal neoplasms
• Online Access: https://www.dovepress.com/patient-considerations-in-metastatic-colorectal-cancer-ndash-role-of-p-peer-reviewed-article-OTT

Jane E Rogers Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Epidermal growth factor receptor (EGFR) is overexpressed in many malignancies, including colorectal cancer (CRC), making EGFR an attractive treatment option. Panitumumab and cetuximab, monoclonal antibodies (mAbs) directed at EGFR, are both currently utilized in the management of metastatic CRC (mCRC). Through the development of these agents in mCRC, key issues surrounding each mAbs use have been revealed. These key issues include negative patient outcome avoidance when determining use, the economic burden with high-cost medication, predictive biomarkers, tumor location, patient geographic location, patient quality of life, and the prevention of debilitating adverse effects. CRC remains a common malignancy, with many of these patients expected to receive targeted therapy, including EGFR mAb therapy. Oncologists must recognize these EGFR mAb factors in order to improve outcomes. This review aims to provide a chronological timeline on the development of panitumumab, clinical pearls, and guidance on the current use of panitumumab in mCRC. Keywords: receptor, epidermal growth factor, antineoplastic agent, antibodies, monoclonal, colorectal neoplasms